Other Routine +

Bausch + Lomb Launches Bi-Blade+(TM) Dual-Port Vitrectomy Cutter in Europe

Bausch + Lomb Expands Surgical Portfolio with European Bi-Blade+ Launch Amidst Guidance Raise

By The Northwire Desk — AI Analysis May 07, 2026 · 07:00 BLCO · 21.93 BAUSCH + LOMB CORPORATION

Executive Summary

Event: Commercial launch of Bi-Blade+(TM) Dual-Port Vitrectomy Cutter in Europe.
Date: May 7, 2026.
Product Details: Advanced dual-port vitrectomy cutter compatible with Stellaris Elite® Vision Enhancement System.
Performance Metrics: Cutting speed increased to 25,000 cuts per minute (vs. 15,000 cpm for Bi-Blade). Flow rate efficiency up 25%. Vibration reduction of 62% at maximum speed.
Fluidics Integration: Adaptive Fluidics software reduces infusion pressure fluctuations by 62%, maintaining intraocular pressure closer to physiologic levels (10–20 mmHg).
Clinical Objective: Designed to minimize retinal traction and increase vitreous flow for retina surgeons.
Context: Follows FDA 510(k) clearance granted on April 8, 2026.

Material Impact

Expectation vs. Reality: The launch is a direct execution of the pipeline milestones outlined in the November 2025 Investor Day and confirmed by the April 8, 2026 FDA clearance. It does not introduce new unexpected data or revenue streams beyond what was priced into the Q1 2026 earnings guidance raise on April 29, 2026.
Segment Impact: Supports the Surgical segment recovery narrative. Management noted in Q1 that Surgical grew only 1% constant currency due to field force rebuild and weather disruptions; this launch provides a new premium product to drive sequential improvement throughout 2026.
Market Positioning: The Bi-Blade+ offers significant technical advantages (speed, flow rate) over the incumbent model, potentially aiding share gain in the vitrectomy cutter market. However, it is an incremental update rather than a disruptive new category.
Risk Assessment: Commercial execution risk remains high given the recent underperformance of the Surgical segment. The Europe launch does not mitigate U.S. field force issues or competitive pressure from other premium IOLs (e.g., PanOptix Pro).

BLCO · Price

Company Overview

Flagship Projects: MIEBO® (dry eye), XIIDRA® (inflammatory dry eye), enVista® IOLs, Stellaris Elite® Surgical System.
Pipeline: $7 billion peak-sales pipeline projected across consumer, pharmaceutical, surgical, and contact lens segments through 2031. Key assets include BL1107 (glaucoma), seeLYRA™ (femtosecond laser), and Elios™ (glaucoma surgery).
Business Model: Diversified revenue streams across Vision Care (Contact Lenses/OTC), Surgical (Equipment/IOLs), and Pharmaceuticals (Rx drops/vitamins).

More from BAUSCH + LOMB CORPORATION